COMPANY
About Us
Board of Directors
Leadership Team
Scientific Advisory Board
Business Development
CONTACT US
SCIENCE
OPTIREACH Technology
Antibody Fragment Technology
Neuroprotective approach for eye diseases
Publications
PIPELINE
Overview
OCS-01 Diabetic Macular Edema
OCS-01 Post Cataract Surgery Inflammation
OCS-02 Dry Eye Disease
OCS-02 Uveitis
OCS-05 Acute Optic Neuritis
OCS-05 Glaucoma
CAREERS
INVESTORS & MEDIA
Overview
Stock Information
News Releases
Events & Presentations
Earnings Calendar
Corporate Governance
SEC Filings
Public Disclosures
Investor FAQs
Investor Resources
COMPANY
About Us
Board of Directors
Leadership Team
Scientific Advisory Board
Business Development
CONTACT US
SCIENCE
OPTIREACH Technology
Antibody Fragment Technology
Neuroprotective approach for eye diseases
Publications
PIPELINE
Overview
OCS-01 Diabetic Macular Edema
OCS-01 Post Cataract Surgery Inflammation
OCS-02 Dry Eye Disease
OCS-02 Uveitis
OCS-05 Acute Optic Neuritis
OCS-05 Glaucoma
CAREERS
INVESTORS & MEDIA
Overview
Stock Information
News Releases
Events & Presentations
Earnings Calendar
Corporate Governance
SEC Filings
Public Disclosures
Investor FAQs
Investor Resources
This content is password protected. To view it please enter your password below:
Password: